Malignant peripheral nerve sheath tumors with high and low Ras‐GTP are permissive for oncolytic herpes simplex virus mutants
- 25 August 2005
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 46 (7) , 745-754
- https://doi.org/10.1002/pbc.20565
Abstract
Background Malignant peripheral nerve sheath tumors (MPNSTs) occur most frequently in patients with neurofibromatosis type 1 and are often fatal. Current therapy relies upon radical surgical resection, which often fails to completely remove the tumor. To address the need for novel treatment approaches for this disease, we sought to determine if human MPNST-derived cell lines are sensitive to oncolytic Herpes simplex virus (oHSV) infection. Activation of the Ras pathway and its inhibitory effects on protein kinase R (PKR) activation have been shown to dictate cellular permissivity to oHSV mutants. Because NF-1-associated MPNSTs possess inherent hyperactive Ras, we hypothesized these tumors would be ideal therapeutic targets for oHSVs. Procedure Human MPNST-derived cell lines were examined for sensitivity to oHSV-mediated gene transduction, virus replication, cytotoxicity, and apoptosis. These parameters were correlated with PKR activation following oHSV infection and compared with normal human Schwann cells (NHSCs) without hyperactive Ras. Results MPNST-derived cell lines were efficiently transduced, supported virus replication and were killed by the oncolytic HSV mutants, including sporadic MPNSTs without hyperactive Ras. In contrast to the highly sensitive MPNST cell lines, NHSCs did not support mutant virus replication. Conclusions MPNSTs are susceptible to lysis by oncolytic HSV mutants, regardless of Ras status. Tumor-selective virus replication in MPNST cells appears to be mediated by both cellular expression of ribonucleotide reductase and prevention of eIF2α phosphorylation. Virus-induced cytotoxicity of MPNST cell lines was caused by both direct lysis and apoptosis. Our data suggest the use of oncolytic HSV mutants may represent a novel treatment approach for patients with MPNSTs.Keywords
This publication has 37 references indexed in Scilit:
- An Oncolytic HSV-1 Mutant Expressing ICP34.5 under Control of a Nestin Promoter Increases Survival of Animals even when Symptomatic from a Brain TumorCancer Research, 2005
- Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyosarcoma xenografts by oncolytic herpes simplex virusesCancer Gene Therapy, 2005
- Intracarotid delivery of oncolytic HSV vector G47Δ to metastatic breast cancer in the brainGene Therapy, 2005
- Oncolytic herpes simplex virus mutants are more efficacious than wild‐type adenovirus Type 5 for the treatment of high‐risk neuroblastomas in preclinical modelsPediatric Blood & Cancer, 2004
- Dominant negative Ras enhances lactogenic hormone‐induced differentiation by blocking activation of the Raf–Mek–Erk signal transduction pathwayJournal of Cellular Physiology, 2004
- Potent antitumor activity after systemic delivery of a doubly fusogenic oncolytic herpes simplex virus against metastatic prostate cancerThe Prostate, 2004
- Review Article : Antiangiogenesis in Neurofibromatosis 1Journal of Child Neurology, 2002
- Therapeutic Efficacy of G207 in a Novel Peripheral Nerve Sheath Tumor ModelExperimental Neurology, 2001
- Angiogenic and invasive properties of neurofibroma Schwann cells.The Journal of cell biology, 1990
- Long-Term Follow-up of von Recklinghausen NeurofibromatosisNew England Journal of Medicine, 1986